Humacyte, Inc. Common Stock (HUMA) is a publicly traded Healthcare sector company. As of September 17, 2026, HUMA trades at $0.58 with a market cap of $155.84M and a P/E ratio of -1.09. HUMA moved +4.15% today. Year to date, HUMA is -42.57%; over the trailing twelve months it is -63.95%. Its 52-week range spans $0.53 to $4.85. Analyst consensus is strong buy with an average price target of $2.06. Rallies surfaces HUMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks HUMA insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $0.58 |
| Market Cap | $155.84M |
| P/E Ratio | -1.09 |
| EPS | $-0.51 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.85 |
| 52-Week Low | $0.53 |
| Volume | 3.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.12M |
| Net Income | $-96.73M |
| Gross Margin | -494.58% |
4 analysts cover HUMA: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.06.